- On 21st November 2018
Coinciding with World COPD Day 2018, The GOLD recommendations for the management of Chronic Obstructive Pulmonary Disease (COPD) have been re-written and published. GOLD (Global Initiative for Chronic Obstructive Lung Disease) works with health care professionals and public health officials to raise awareness of COPD and to improve prevention and treatment of this lung disease for patients around the world. Its recommendations for COPD care are shaped by a science committee made up of leading experts from around the world.
The most notable change to this year’s newly-published GOLD report is related to how inhaled COPD treatments are used. A more personalised approach is taken, in line with a global drive towards precision medicine, so that inhaled treatments are prescribed in a manner which increases the possibility of benefit and decreases the possibility of harm to each individual patient.
This personalised approach has three main considerations for each patient:
- The degree of symptoms
- The number of exacerbations
- The blood eosinophil count
The patient’s blood eosinophil count is now being used to guide therapy with inhaled corticosteroids, so that patients receiving these drugs are those who will receive the greatest benefit. This again reflects the movement towards precision medicine – an individualised, personalised approach, whereby as much clinical and biological information as possible is used to decide on the right treatment.
Professor Dave Singh, Medical Director of the Medicines Evaluation Unit, sits on the GOLD Science Committee and was involved in the writing of this new report:
“The new GOLD recommendations offer the opportunity for better treatment outcomes for patients. By using a more selective and targeted approach to the prescribing of inhaled treatments, I believe we can more effectively treat symptoms and exacerbations.” – Professor Dave Singh
GOLD and the MEU
The GOLD Committee recommends the use of combination inhalers (inhalers which contain two or three medicines). Many of the MEU’s studies have contributed to the development of these treatments, most notably Chiesi’s Trimbow® triple therapy inhaler. This was the first triple therapy to be launched in the UK and the MEU carried out the majority of early phase studies for this treatment. This demonstrates the extent to which the MEU has contributed to the treatment and improvement of COPD patients’ lives.
You can read the newly-released GOLD Reports in full here.